Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Q2 2017 · 10-Q
Revenue$282.16M$282.16M+13.2% vs Q2 2016 Net Income$10.84M$10.84M−15.1% vs Q2 2016 EPS Diluted$0.14$0.14−12.5% vs Q2 2016 Gross Profit$183,166,000+14.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
Operating Cash Flowderived$28,871,000−24.2% Free Cash Flowderived$16,052,000−46.2% Margins · derivedGross margin64.9%+0.8 pt vs Q2 2016
Operating margin6.0%−3.0 pt vs Q2 2016
Net margin3.8%−1.3 pt vs Q2 2016
ended Jun 30, 2017 · filed Jul 26, 2017 · 26 d after period end